Research location

Rennes

France

Published trials939

Site observations963

Linked trials published939

Page2 / 19

Research activity in Rennes

France

CureCurrent currently publishes aggregate city-level research activity for this location: 939 trials and 963 site observations.

The map is centered on registry-derived city coordinates. Circle size reflects published trial activity.

Below are current trials with one or more ClinicalTrials.gov site observations in this city. Results are paginated 50 per page, with recruiting studies shown first.

Trials with sites in Rennes

939 linked trials · page 2 of 19

Belief Update: The Effects of Depression and Antidepressants in Older PeopleNCT07681492 · 2025-01-14 · 2 site observations

Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung CancerNCT06712316 · 2025-01-07 · 1 site observation

Pembrolizumab and Chemotherapy Treatment or no Treatment Guided by the Level of TILs in Resected Early-stage TNBCNCT06078384 · 2024-12-27 · 1 site observation

Feasibility and Efficacy of rTMS in Depression in Patients With Autism Spectrum Disorder (ASD)NCT07258914 · 2024-12-19 · 1 site observation

Prospective, Longitudinal Biocollection in Thoracic Oncology, Including Newly Diagnosed Lung Cancer PatientsNCT06481813 · 2024-12-10 · 1 site observation

A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Non-Squamous NSCLCNCT06627647 · 2024-11-27 · 1 site observation

A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)NCT06692738 · 2024-11-18 · 1 site observation

Role of High-Throughput Whole Genome Sequencing for the Diagnosis and Care of Atypical DiabetesNCT06570278 · 2024-10-30 · 1 site observation

Phase II Efficacy Study of Repotrectinib in Frail and/or Elderly Patients With ROS1-rearranged Advanced NSCLCNCT06552234 · 2024-10-01 · 1 site observation

PROspective Master-protocol for Evaluation of Systemic THErapeutics in Elderly With Thoracic MalignanciesNCT06646471 · 2024-09-26 · 1 site observation

Standard of Care +/- 177Lu-PSMA-617 In de Novo mHSPC Patients With Poor PSA Response (PEACE6-Poor Responders)NCT06496581 · 2024-09-12 · 1 site observation

A Study of I-DXd in Combination With Atezolizumab With or Without Carboplatin as First-Line Induction or Maintenance in Subjects With Extensive Stage-Small Cell Lung Cancer (IDeate-Lung03)NCT06362252 · 2024-07-22 · 1 site observation

MIMA Pilot Study: MIcrostructure of the Medial Temporal Lobe in Early Alzheimer's DiseaseNCT06099587 · 2024-07-02 · 1 site observation

Cardiac Amyloidosis pRevaleNce of in OLDer Subjects Affected by Heart FailureNCT06427304 · 2024-07-01 · 1 site observation

Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has SpreadNCT06324357 · 2024-06-28 · 1 site observation

FIRST-NEC (GFPC 01-2022) - Combination of Durvalumab With Etoposide and PlatinumNCT06393816 · 2024-06-13 · 1 site observation

Identification of Risk Factors for Brain Recurrence in Patients With HER2-positive Localised Breast CancerNCT06358625 · 2024-06-06 · 1 site observation

A Study of Mavorixafor in Participants With Congenital and Acquired Primary Autoimmune and Idiopathic Chronic Neutropenic Disorders Who Are Experiencing Recurrent and/or Serious InfectionsNCT06056297 · 2024-06-06 · 1 site observation

ECLECTIC: EstroTEP and Circulating Biomarkers for ER-positive HER2-negative Metastatic Breast Cancer PatientsNCT06195709 · 2024-05-27 · 1 site observation

A Study of Ifinatamab Deruxtecan Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung CancerNCT06203210 · 2024-05-21 · 1 site observation

Study to Evaluate the Effect of Balcinrenone/Dapagliflozin in Patients With Heart Failure and Impaired Kidney FunctionNCT06307652 · 2024-04-12 · 1 site observation

Remotely Supervised Computerized Cognitive Stimulation to Reduce Post-chemotherapy Cognitive Difficulties in Patients Treated for Localized Breast CancerNCT06027632 · 2024-02-09 · 1 site observation

Evaluation of the Medical Benefit of Spa Therapy on Fibrosis After Radiotherapy for Breast Cancer or UADT (Upper Aerodigestive Tract) CancerNCT05874492 · 2024-01-29 · 1 site observation

A Prospective Cohort Study to Evaluate Molecular pRognostic Factors and Resistance Mechanisms to Osimertinib in Adjuvant Treatment of Completely Resected pIB-IIIA Non-small Cell Lung Carcinoma With Common EGFR Mutations (L858R and Del19)NCT06053099 · 2024-01-22 · 1 site observation

Impact of Continuous Positive Airway Pressure on the Occurrence of Acute Exacerbations of COPD in Patients With COPD-OSA Overlap Syndrome (CO-OS)NCT05958563 · 2024-01-09 · 1 site observation

A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung CancerNCT06119581 · 2023-12-21 · 1 site observation

Efficiency of a Composite Personalised Care on Functional Outcome in Early PsychosisNCT05796401 · 2023-12-15 · 1 site observation

BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid TumorsNCT06120283 · 2023-12-01 · 1 site observation

A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)NCT05920356 · 2023-11-16 · 1 site observation

Network-based biOmarker Discovery of Neurodegenerative Diseases Using Multimodal ConnectivityNCT06080659 · 2023-11-06 · 1 site observation

Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC PatientsNCT05899608 · 2023-10-26 · 1 site observation

DESTINY Breast Respond HER2-(Ultra)Low EuropeNCT05945732 · 2023-10-24 · 1 site observation

The ReTAVI Prospective Observational RegistryNCT05601453 · 2023-09-05 · 1 site observation

Aspirin for the Prevention of Preeclampsia and Pregnancy Outcomes After Assisted Reproductive TechnologyNCT05625724 · 2023-08-02 · 1 site observation

IPH5201 and Durvalumab in Patients With Resectable Non-Small Cell Lung Cancer (MATISSE)NCT05742607 · 2023-06-23 · 1 site observation

A Study Evaluating the Efficacy and Safety of Inavolisib Plus Fulvestrant Compared With Alpelisib Plus Fulvestrant in Participants With HR-Positive, HER2-Negative, PIK3CA Mutated, Locally Advanced or Metastatic Breast Cancer Post CDK4/6i and Endocrine Combination TherapyNCT05646862 · 2023-06-07 · 1 site observation

RItuximab Versus Ocrelizumab in Relapsing-remitting Multiple Sclerosis.NCT05758831 · 2023-06-01 · 1 site observation

EMITT-1 (ERAP Mediated Immunopeptidome Targeting Trial - 1)NCT06923761 · 2023-05-21 · 1 site observation

Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive MalignanciesNCT05786924 · 2023-04-18 · 1 site observation

A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine TherapyNCT05774951 · 2023-03-31 · 1 site observation

Intensification of Blood Pressure Lowering Therapeutics Based on Diuretics Versus Usual Management for Uncontrolled Hypertension IN Patients With Moderate to Severe Chronic Kidney DiseaseNCT05732727 · 2023-03-28 · 1 site observation

Cost-utility of Focal HIFU vs ProstatectomyNCT05710861 · 2023-03-06 · 1 site observation

Impact of First-trimester Preeclampsia Screening on Perinatal and Maternal Morbidity (RANSPRE)NCT05521776 · 2023-03-06 · 1 site observation

Pulmonary Vein Isolation Alone or in Combination With Substrate Modulation After Electric Cardioversion FailureNCT05264831 · 2023-02-20 · 1 site observation

Dose-finding and Dose Expansion Study of OSE-279 in Subjects With Advanced Solid Tumors or LymphomasNCT05751798 · 2022-12-20 · 1 site observation

Study to Determine the Safety and Pharmacokinetics of DO-2 in Patients With Advanced or Refractory Solid TumoursNCT05752552 · 2022-12-20 · 1 site observation

Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)NCT05633654 · 2022-12-12 · 1 site observation

Cardioverter DefIbriIlator PlacEMent for priMary Prevention of Sudden cArdiac Death in Patients Older Than 70 YearsNCT05373940 · 2022-06-29 · 1 site observation

Study Evaluating DNA Double-strand Breaks (DSBs) REpair Factors (POLQ, Shieldin Complex and 53BP1) Expression as Biomarker of PARP Inhibitor Resistance in Patients With Deleterious Germline Mutation in BRCA 1/2 and HER2-negative, Metastatic or Locally Advanced Breast Cancer.NCT05378204 · 2022-06-23 · 1 site observation

Evaluation of the Individual Early Psychoeducation Program for Schizophrenic Disorders in InpatientsNCT05329363 · 2022-06-17 · 1 site observation

How to interpret this record

CureCurrent links normalized diseases, medicines, registry study labels, sponsors and research sites. A link is not the same as a finding of clinical effectiveness. Our research guides explain how to compare studies, decode RxNorm identities, and avoid over-interpreting site and trial counts. See the published database coverage for mapping completeness.

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.